Page 10 - CIMA SCS Workbook November 2018 - Day 2 Tasks

CIMA NOVEMBER 2018 – STRATEGIC CASE STUDY

Reference Materials – proposal on NX1

Proposal

To: Research Committee
From: Senior Scientist
Subject: Research on NX1

As part of our work on researching other areas of illness, we believe we might have created a
compound (termed for research purposes as NX1) which can address most of the serious
symptoms of Algernon’s Disease. This illness is found in remoter parts of sub-Saharan Africa, and
is reckoned to affect 0.7 in every 1,000 inhabitants.

There is no known cure for Algernon’s Disease, which can have crippling and even life-threatening
effects. Information on reported outbreaks is uncertain, as many of those incidents that have
occurred have been in poor economies where communications are limited and the inhabitants
live in remote areas. The World Health Organisation suggests that, in the last major outbreak in
2015, around 20,000 people were affected.

I believe that Novak has an opportunity to invest in an area of drug research that has not been
addressed by any of our competitors, and would ask the Research Committee to authorise an
initial budget of C$200 million on NX1.

26 KAPLAN PUBLISHING